Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$4.07 - $9.0 $53,186 - $117,612
-13,068 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.11 - $13.91 $218,418 - $374,624
-26,932 Reduced 67.33%
13,068 $118,000
Q2 2021

Aug 16, 2021

BUY
$15.95 - $19.6 $638,000 - $784,000
40,000 New
40,000 $784,000

Others Institutions Holding AMAM

About Ambrx Biopharma Inc.


  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.